No abstract

No abstract

No abstract

No abstract

No abstract

Arzoxifene suppressed bone turnover and increased BMD. Within the limitations of this study, the endometrial safety profile of arzoxifene appeared similar to that of raloxifene. While no clear dose effect was evident, arzoxifene 20 and 40 mg/day appeared the optimal doses for reducing bone turnover.

No abstract

plemental screening and the selection of appropriate treatment should be based on characteristics associated with ipsilateral recurrence. Standard definitions of breast cancer end points should be adopted to permit consistent comparison with the treatment literature. Disclosures of Conflicts of Interest: P.B.G. disclosed no relevant relationships. W.A.B. disclosed no relevant relationships. R.C.J. disclosed no relevant relationships. References 1. Kim SY, Han BK, Kim EK, et al. Breast cancer detected at screening US: survival rates and clinical-pathologic and imaging factors associated with recurrence. Radiology 2017;284(2):354-364. 2. Definitions of recurrent and metastatic cancer. Breastcancer.org website. http://www. breastcancer.org/symptoms/types/recur_ metast/definitions. Accessed August 7, 2017. 3. Hudis CA, Barlow WE, Constantino JE, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.